Merck partially regains its breakthrough tag for hep C combo

Merck ($MRK) execs weren't happy when the FDA stripped its breakthrough therapy designation for their closely watched hepatitis C combo. But the agency has now relented--at least partly. The pharma giant said it's getting two new BTD titles in small subgroups of patients to replace the broader breakthrough tag that it lost. Report

Suggested Articles

Move over, Roche. There’s a new small-cell lung cancer therapy on the scene, and it belongs to AstraZeneca.

Gilead CEO promised to make remdesivir affordable, shortly after the company backed off its request for orphan status amid a public backlash.

Weeks after launching a U.S. trial to evaluate IL-6 inhibitor Kevzara for COVID-19, Sanofi and Regeneron have launched a matching study abroad.